On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Comprehensive Cancer Centers of Nevada

InstitutionResearch output, impact & collaborations

Comprehensive Cancer Centers of Nevada is a institution indexed in ScholarIQ from OpenAlex.

What is known about Comprehensive Cancer Centers of Nevada?

ScholarIQrecord summary

Comprehensive Cancer Centers of Nevada is a research organisation in Las Vegas, US. OpenAlex records 1,231 works and 73,701 citations for it. 125 researchers list it as their most recent affiliation.

How many works does Comprehensive Cancer Centers of Nevada have?

ScholarIQindexed works

Comprehensive Cancer Centers of Nevada has 1,231 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Comprehensive Cancer Centers of Nevada →

How many citations does Comprehensive Cancer Centers of Nevada have?

ScholarIQcitation count

Comprehensive Cancer Centers of Nevada has 73,701 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Comprehensive Cancer Centers of Nevada →

How many researchers are at Comprehensive Cancer Centers of Nevada?

ScholarIQresearcher count

Comprehensive Cancer Centers of Nevada has 125 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Comprehensive Cancer Centers of Nevada?

ScholarIQavg h-index

Comprehensive Cancer Centers of Nevada has an average h-index of 116 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Comprehensive Cancer Centers of Nevada?

ScholarIQror

The ROR for Comprehensive Cancer Centers of Nevada is on the source record.

Open the ROR →

What is the OpenAlex record for Comprehensive Cancer Centers of Nevada?

ScholarIQopenalex

The OpenAlex for Comprehensive Cancer Centers of Nevada is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Comprehensive Cancer Centers of Nevada?

ScholarIQtop researchers by citations

Nicholas J. Vogelzang · Prostate Cancer Treatment and Research

1,125 works69,898 citations

What are the most-cited papers on Comprehensive Cancer Centers of Nevada?

ScholarIQmost cited works

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin

New England Journal of Medicine. 20173,424 CitationsOPEN ACCESS

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

Christopher J. Sweeney, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Mario A. Eisenberger, Yu-Ning Wong, Noah M. Hahn, Manish Kohli, Matthew M. Cooney, Robert Dreicer, Nicholas J. Vogelzang, Joel Picus, Daniel H. Shevrin, Maha Hussain, Jorge A. García, Robert S. DiPaola

New England Journal of Medicine. 20152,869 CitationsOPEN ACCESS

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

Christos E. Kyriakopoulos, Yu‐Hui Chen, Michael A. Carducci, Glenn Liu, David F. Jarrard, Noah M. Hahn, Daniel H. Shevrin, Robert Dreicer, Maha Hussain, Mario A. Eisenberger, Manish Kohli, Elizabeth R. Plimack, Nicholas J. Vogelzang, Joel Picus, Matthew M. Cooney, Jorge A. García, Robert S. DiPaola, Christopher J. Sweeney

Journal of Clinical Oncology. 20181,116 CitationsOPEN ACCESS

Intermittent versus Continuous Androgen Deprivation in Prostate Cancer

Maha Hussain, Catherine M. Tangen, Donna L. Berry, Celestia S. Higano, E. David Crawford, Glenn Liu, George Wilding, Stephen M. Prescott, S.K. Sundaram, Eric J. Small, Nancy A. Dawson, Bryan Donnelly, Peter Venner, Ulka N. Vaishampayan, Paul F. Schellhammer, David I. Quinn, Derek Raghavan, Benjamin Ely, Carol M. Moinpour, Nicholas J. Vogelzang, Ian M. Thompson

New England Journal of Medicine. 2013574 CitationsOPEN ACCESS

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

Gerald S. Falchook, Karl D. Lewis, Jeffrey R. Infante, Michael S. Gordon, Nicholas J. Vogelzang, Douglas J. DeMarini, Peng Sun, Christopher Moy, Stephen A. Szabo, Lori Roadcap, Vijay Peddareddigari, Peter F. Lebowitz, Ngocdiep T. Le, Howard A. Burris, Wells A. Messersmith, Peter J. O’Dwyer, Kevin B. Kim, Keith T. Flaherty, Johanna C. Bendell, René González, Razelle Kurzrock, Leslie A. Fecher

The Lancet Oncology. 2012545 CitationsOPEN ACCESS

How much of the research on Comprehensive Cancer Centers of Nevada is open access?

ScholarIQopen access share

100%OPEN ACCESS

Gold

Green

50%

Hybrid

Bronze

50%

Closed